Last reviewed · How we verify
DW5421A
DW5421A is a small molecule that targets the SGLT2 receptor.
DW5421A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DW5421A |
|---|---|
| Sponsor | Daewon Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DW5421A works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in decreased blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |